Skip to main content
. Author manuscript; available in PMC: 2013 Sep 10.
Published in final edited form as: J Pharmacol Exp Ther. 2008 Mar 26;326(1):1–11. doi: 10.1124/jpet.107.135830

Table 1. NF90-8 cell cycle analysis.

NF90-8 cells were treated as indicated above for 24 or 48 hours. Data represent the mean ± SD of three independent experiments.

DNA analysis of NF90-8 MPNST cells
G1 G2 S Apoptosis
0 Hours
Untreated 32.0% ± 3.7 37.4% ± 0.8 30.6% ± 4.3 0.2% ± 0.4
24 Hours

DMSO 40.0% ± 2.1 29.0% ± 2.7 30.8% ± 5.2 1.3% ± 0.3
500 nM lovastatin 40.0% ± 2.3 24.5% ± 2.8 35.3% ± 1.2 2.0% ± 0.4
500 nM 1 41.1% ± 1.8 24.7% ± 2.9 34.2% ± 1.3 1.7% ± 0.3
500 nM 1 + 500 nM lovastatin 50.2% ± 2.0 * 25.9% ± 2.0 23.9% ± 3.0 12.6% ± 1.8 *
500 nM 2 41.5% ± 1.6 26.5% ± 2.2 32.0% ± 3.6 1.5% ± 0.5
500 nM 2 + 500 nM lovastatin 49.6% ± 3.4 * 26.2% ± 1.3 24.2% ± 2.7 5.9% ± 0.9
48 Hours

DMSO 44.4% ± 2.4 23.3% ± 2.3 32.3% ± 1.9 2.7% ± 0.4
500 nM lovastatin 46.7% ± 2.6 26.4% ± 1.4 26.9% ± 1.9 3.6% ± 1.0
500 nM 1 43.0% ± 2.5 24.4% ± 1.6 32.6% ± 2.4 3.0% ± 0.7
500 nM 1 + 500 nM lovastatin 62.7% ± 2.9 * 31.0% ± 2.0 6.3% ± 1.1 * 31.4% ± 6.3 *
500 nM 2 40.2% ± 1.3 26.0% ± 1.6 33.9% ± 0.7 1.8% ± 0.7
500 nM 2 + 500 nM lovastatin 55.0% ± 1.0 * 27.0% ± 5.2 18.0% ± 14.8 30.3% ± 3.4 *
*

Statistical significance was determined between the FTI/lovastatin treated cultures and the DMSO controls. Significance was set at p<0.05.